A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
A phase 2 trial of Plitidepsin in Multiple myeloma, run by PharmaMar, completed.
Overview
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT00229203 by PharmaMar, with 51 participants recorded, started 2005-02 and reaching its primary completion in 2008-08. Interventions recorded: Plitidepsin. Conditions recorded: Multiple Myeloma.
Linked to the drug Plitidepsin because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialAplidin - Dexamethasone in Relapsed/Refractory Myeloma
Shares Plitidepsin, PharmaMar, Multiple myeloma and the tag pipeline.
- TrialEfficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
Shares Plitidepsin and the tag pipeline.
- TrialStudy of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
Shares PharmaMar and the tag pipeline.
- TrialStudy of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
Shares PharmaMar and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialMeasurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Shares Multiple myeloma and the tag pipeline.